The global cancer/tumor profiling market size is expected to reach USD 15.32 billion by 2027 according to a new study by Polaris Market Research. The report “Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Application (Personalized Medicine, Diagnostics, Prognostics, Biomarker Discovery, Research); By Regions – Segment – Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing demand for tumor profiling and diagnosis and therapy techniques is driven by oncologists. Increased use of biomarkers in tumor profiling and increasing use of next-generation cancer profiling sequencing methods are some of the main factors driving the growth of the tumor profiling market. Tumor profiling is used to evaluate the metabolism, properties, and mutations of the tumor that can assist discover effective therapies.

Drugs that target these mutated kinases can be discovered and developed based on genetic modification. The profiling is considered a requirement to increase the sensitivity of kinases-focused medications because they rely on individual tumors genetic composition. Thus, these mutated profiles of DNA tumors help to create specific anticarcinogenic treatments.

Globally there is a rise in cancer patients every year. According to the WHO this disease is considered to be the second leading cause mortalities in the year 2019. It is also estimated that that 1 out of 6 deaths were due to cancer. WHO has marked that one third of deaths from this disease are due to 5 leading behavioral and dietary risks. The factors include high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol use. Tobacco is one of the leading factors for the rise in the prevalence of cancer and mortalities that approximately 22%.

According to WHO, in 2015, there were around 17.6 million cases related to cancer that increases to 18.1 million cases in 2018 and nearly 9.6 million mortalities. The rising number of patients is the major factor for the growth of global cancer/tumor profiling market.

Certified techniques have been identified that can reduce the time taken to identify tumors and stages of advancement along with improved support for cancer research. Moreover, major investments by major biotechnology companies for the development of new therapies and new techniques of drug design are being witnessed across countries. This has significantly driven market growth and is expected to sustain growth during the forecast period. Biomarkers play a significant part in the design of a drug regime for cancer patients by quickly developing gene profiling techniques and individualizing targeted therapies.

Currently, genome based prognostic biomarkers can be used to prognosticate multiple kinds of cancer in the clinical phases. Researchers, however, contend that conversion difficulties are hindering the broad divide between the phase of biomarker discovery and their clinical conversion. The acquisition of tumor genomic data is seen as the most significant step in cancer prediction, diagnosis, and therapy.

Next Generation Sequencing (NGS) is a sophisticated technique for the sequence that can be used for accurate tumor DNA genomic sequencing. The interpreted data contribute much more quickly to the assessment of tumor purity and the magnitude of disease progression. The primary benefit of NGS is the complete exotic sequence which helps examine all protein-coding areas of the human genome. It also enables whole genome sequencing to be useful for analysis of protein coding and non-coding areas in the human genome. Such advances in technology are one of the primary drivers of global cancer/tumor profiling market.

Moreover, the growing demand for personalized medicine further provides substantial opportunities for the tumor profiling market. The personalized medicine is defined as typical care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personal medicine based on the patients.  Several factors should be considered before providing personal medicine to a patient. Firstly, the doctors have to detect the type or the symptoms of cancer that can be developed in a patient.

Detection is important for the surgeon or the doctor, to find the best suited therapy that can treat the person. For developing a personalized medicine tumor profiling need to be taken into account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of disease.